[Infliximab(chimeric monoclonal antibody to tumor necrosis factor alpha)].
In rheumatoid arthritis and inflammatory bowel disease, such as Crohn's disease, certain immunological abnormalities are considered as its cause, but the fundamental mechanism remains unclear. However, recent researches revealed that inflammatory cytokines, such as TNF-alpha, IL-1 and IL-6, are greatly involved in these immunological abnormalities. This led to the development of anti-cytokine therapy using monoclonal antibodies to these cytokines. Among them, Infliximab, a chimeric monoclonal antibodies to TNF-alpha, is most clinically applied and marked therapeutic effect is seen in various diseases.
Hibi
Toshifumi
T
Department of Internal Medicine, Keio University School of Medicine.
Yoshizawa
Shigeo
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy; D003602:Cytotoxicity, Immunologic; D006801:Humans; D000069285:Infliximab; D007412:Intestinal Fistula / Q000188:drug therapy; D051379:Mice; D015202:Protein Engineering; D011993:Recombinant Fusion Proteins; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab